Jin Chengyan, Zhang Xingyi, Sun Mei, Zhang Yifan, Zhang Guangxin, Wang Bin
Department of Thoracic Surgery.
Department of Pathology, The Second Affiliated Hospital of Jilin University, Changchun, People's Republic of China.
Onco Targets Ther. 2016 Sep 6;9:5483-8. doi: 10.2147/OTT.S102386. eCollection 2016.
Given the lack of clarity on the expression status of SRC1 protein in breast cancer, we attempted to ascertain the clinical implications of the expression of this protein in breast cancer.
Samples from 312 breast cancer patients who were followed up for 5 years were analyzed in this study. The associations of SRC1 expression and clinicopathological factors with the prognosis of breast cancer were determined.
The 312 breast cancer patients underwent radical resection, and 155 (49.68%) of them demonstrated high expression of SRC1 protein. No significant differences were found for tumor size, estrogen receptor expression, or progesterone receptor expression (P=0.191, 0.888, or 0.163, respectively). It is noteworthy that SRC1 expression was found to be related to HER-2 and Ki-67 expression (P=0.044 and P=0.001, respectively). According to logistic regression analysis, SRC1 expression was also significantly correlated with Ki-67 and HER-2 expression (P=0.032 and P=0.001, respectively). Survival analysis showed that patients with a high expression of SRC1 and NANOG and those with SRC1 and NANOG coexpression had significantly poorer postoperative disease-specific survival than those with no expression in the HER-2-positive group (P=0.032, 0.01, and P=0.01, respectively).
High SRC1 protein expression was related to the prognosis of HER-2-overexpressing breast cancers.
鉴于乳腺癌中SRC1蛋白表达状态尚不明确，我们试图确定该蛋白表达在乳腺癌中的临床意义。
本研究分析了312例接受了5年随访的乳腺癌患者的样本。确定了SRC1表达及临床病理因素与乳腺癌预后的关联。
312例乳腺癌患者接受了根治性切除，其中155例（49.68%）表现出SRC1蛋白高表达。在肿瘤大小、雌激素受体表达或孕激素受体表达方面未发现显著差异（P分别为0.191、0.888或0.163）。值得注意的是，发现SRC1表达与HER-2和Ki-67表达相关（P分别为0.044和0.001）。根据逻辑回归分析，SRC1表达也与Ki-67和HER-2表达显著相关（P分别为0.032和0.001）。生存分析表明，在HER-2阳性组中，SRC1和NANOG高表达的患者以及SRC1和NANOG共表达的患者术后疾病特异性生存率明显低于无表达的患者（P分别为0.032、0.01和0.01）。
SRC1蛋白高表达与HER-2过表达乳腺癌的预后相关。
